Laboratory Assays in the Clinical Management of Antiretroviral Therapy

  • Author: Mark Holodniy, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 12/12/17 (What's New)

Summary

  • Current guidelines recommend genotypic resistance testing for all HIV-infected persons at entry into care regardless of whether antiretroviral therapy will be initiated (Management Guidelines)[DHHS ART]
  • If antiretroviral therapy is deferred, repeat resistance testing should be considered at the time of treatment initiation, particularly in patients at risk of transmission of drug-resistant virus
  • If transmitted resistance to integrase inhibitors is suspected, providers may opt to supplement standard testing with an integrase inhibitor genotypic resistance test 

Action required

Keywords: Resistance Testing

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.